Patients with Crohn's disease who are considered high-risk as determined by capsule endoscopy but are in clinical remission benefit from a treat-to-target strategy, a new study shows.
Celltrion today presented positive twoyear results from the extended LIBERTY studies LIBERTYCD1 and LIBERTYUC2 in patients with moderately to severely active Crohns disease CD and ulcerative colitis UC. Celltrion also presented endoscopic outcomes from the posthoc analysis of the LIBERTYCD study.3
Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
22.02.2024 - Results of the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis to be highlighted in oral presentation on February 22nd SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) - Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a . Seite 1
Crohn’s Colitis Cure (CCCure) today announced its first subscription member to its world-leading inflammatory bowel disease (IBD) clinical management system, Crohn’s Colitis Care (CCCare)